Matthew Herper

Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.

A personalized cancer vaccine developed by Moderna and Merck may be a triumph of immunology and cancer biology. It might also be the triumph of an algorithm.

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and pandemic-era complications.

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

It's no mystery. History tells us that President Trump’s executive order calling for the MMR to be split into separate shots could do real harm.

Kalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The Readout

Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology right now.

Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with

Closely watched Pfizer lung cancer drug falls short in clinical trial | STAT

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.